GLP‑1 Peptide Long‑Acting Injectable
Metabolic Disease
PreclinicalActive
Key Facts
About Mapi Pharma
Israeli biotech developing long‑acting depot injectables for neurology and pain.
View full company profileTherapeutic Areas
Other Metabolic Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| DVI-004 | Divamics | Preclinical |
| Undisclosed Peptide Programs | AmideBio | Preclinical |
| Undisclosed | Junevity | Pre-clinical |
| Stabilized Peptide Therapeutics (e.g., GLP-1) | Constructive Bio | Pre-clinical |
| RZ-858 | Rezubio | Preclinical |